You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

Claims for Patent: 5,605,690

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,605,690

Title:	Methods of lowering active TNF-.alpha. levels in mammals using tumor necrosis factor receptor
Abstract:	A method for treating TNF-dependent inflammatory diseases in a mammal by administering a TNF antagonist, such as soluble TNFR.
Inventor(s):	Jacobs; Cindy A. (Seattle, WA), Smith; Craig A. (Seattle, WA)
Assignee:	Immunex Corporation (Seattle, WA)
Application Number:	08/385,229
Patent Claims:	1. A method for lowering the levels of active TNF-.alpha. in a mammal in need thereof which comprises administering to said mammal a TNF-lowering amount of a TNF antagonist selected from the group consisting of: (a) a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1; and (b) a chimeric antibody comprising a TNF receptor according to (a) fused to the constant domain of an immunoglobulin molecule. 2. A method for lowering the levels of active TNF-.alpha. in a mammal in need thereof which comprises administering to said mammal a TNF-lowering amount of a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1. 3. A method for lowering the levels of active TNF-.alpha. in a mammal in need thereof which comprises administering to said mammal a TNF-lowering amount of a chimeric antibody comprising a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1 fused to the constant domain of an immunoglobulin molecule. 4. A method for lowering the levels of active TNF-.alpha. in a mammal having arthritis, which comprises administering to such mammal a therapeutically effective amount of a TNF-antagonist selected from the group consisting of: (a) a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1; and (b) a chimeric antibody comprising a TNF receptor according to (a) fused to the constant domain of an immunogloblin molecule. 5. A method for lowering the levels of active TNF-.alpha. in a mammal having arthritis, which comprises administering to said mammal a TNF-lowering amount of a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1. 6. A method for lowering the levels of active TNF-.alpha. in a mammal having arthritis, which comprises administering to said mammal a TNF-lowering amount of a chimeric antibody comprising a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1 fused to the constant domain of an immunoglobulin molecule.

Details for Patent 5,605,690

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	November 02, 1998	⤷ Sign Up	2014-02-25
Immunex Corporation	ENBREL	etanercept	For Injection	103795	May 27, 1999	⤷ Sign Up	2014-02-25
Immunex Corporation	ENBREL	etanercept	Injection	103795	September 27, 2004	⤷ Sign Up	2014-02-25
Immunex Corporation	ENBREL	etanercept	Injection	103795	February 01, 2007	⤷ Sign Up	2014-02-25
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	September 14, 2017	⤷ Sign Up	2014-02-25
Immunex Corporation	ENBREL	etanercept	Injection	103795		⤷ Sign Up	2014-02-25
Immunex Corporation	ENBREL	etanercept	Injection	103795	March 05, 2020	⤷ Sign Up	2014-02-25
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 5,605,690

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Austria	E131871	⤷ Sign Up
Austria	E242322	⤷ Sign Up
Australia	3970293	⤷ Sign Up
Australia	4920993	⤷ Sign Up
Australia	6178190	⤷ Sign Up
Australia	630497	⤷ Sign Up
Australia	670125	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.